EZH2 and bladder transitional cell carcinoma: Taken together, our preliminary in vitro data do neither support the concept of an anti-regulation between ARID1A and EZH2 in urothelial cells nor ARID1A-deficiency as a suitable predictive biomarker for EZH2-inhibitor treatment response in urothelial bladder cancer.